Generate:Biomedicines has entered a strategic collaboration with the Roswell Park Comprehensive Cancer Center in Erie County, New York, US, to accelerate the development of new oncology cell therapies leveraging generative artificial intelligence.
The partnership will focus on the discovery and development of chimeric antigen receptor (CAR) T-cell therapies and armouring technologies for up to three targets, including ovarian cancer and other solid tumours.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The companies will collaborate to develop optimised cell therapies involving the engineering of a patient’s T cells to recognise and destroy tumours.
The collaboration leverages the Generate platform’s programmability and scalability along with Roswell Park’s cell therapy design, clinical development and manufacturing expertise.
Generate:Biomedicines and Roswell Park will divide costs related to research and development, and profits derived from the commercialisation of products resulting from their collaboration.
Roswell Park will function as a location for Phase I and II clinical trials, as well as recommend lead investigators.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNew York Governor Kathy Hochul recently revealed that Roswell Park Comprehensive Cancer Center in Buffalo will host a $98m cell and gene therapy hub.
The ongoing collaboration builds on the momentum generated by the new hub, partly funded by New York State, which will transform Roswell Park’s current good manufacturing practice facilities into the largest academic cell therapy centre in the US.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
